CORTEX PHARM INC (COR) has had 889890 shares shorted at a volume weighted average short price of $2.800. $1,779,780.00 was shorted at this level and may begin short squeezing imminently. This represents a portion of the total short volume since January 2005. To see all the data, please visit SqueezeTrigger.com . As of September 10th, the Total Short Interest was 835102 shares. There are $2,338,285.60 worth of shares that have been shorted and have not yet covered.

From one of the press releases:

"The Company expects to have further toxicological information available toward the end of this year, after completion of three-month toxicology trials in both monkeys and rats. "

So, they have completed 3 month tox studies and have more tox results to come.

The FDA dosing restriction was not a surprise to Stoll and it shouldn't be a surprise to us. The FDA is just trying to be as conservative as possible, which is the same reason the hold was introduced in the first place.

I believe I made a mistake in my last posting. Here it is:

"Therefore, COR is aiming to restore glutamate levels for most diseases."

Ampakines don't restore glutamate levels. Instead, they improve communication to the receptor. Glutamate is produced by the neurotransmitter. With Ampakines, one gets a more excited response from the neuroreceptor.

Therefore, what may seem like a paradox could be explained by the fact that neurodegeneration can occur from increased levels of glutamate, but increasing the response to whatever amount of glutamate is produced has been found to actually upregulate BDNF, and is neuroprotective and neuroregenerative.

I'm not a scientist by any means. However, I believe this explanation is accurate. I'd check it with Neuroinvestment on the Yahoo board.

I am positive, however, that Ampakines don't focus on the transmission of glutamate, but rather the AMPA receptor, which receives the glutamate.

Here is an excerpt from the COR website (cortexpharm.com):

"A reduced level of glutamate-mediated excitatory stimulation has been implicated in Alzheimer’s disease, schizophrenia, and a number of other diseases and disorders. Cortex’s Ampakine drugs enhance excitatory communication, thereby partially or completely restoring the reduced levels of glutamate-mediated communication in these diseases."

Therefore, COR is aiming to restore glutamate levels for most diseases. Also, in all studies I've read, Ampakines have been found to be neuroprotective and neuroregenrative, not neurodegenerative.

Dr. Rogers, one of the founders of Ampakine technology, has stated that spaced treatment of Ampakines is necessary in long-term treatment to avoid a negative feedback loop. Therefore, I suspect that the eventual dosing regimen, when CX-717 comes to market, will include spaced treatments. How much spacing is required? Probably only Drs Rogers and Lynch have the background to give you an educated answer.

Also, remember that low-impact and high-impact Ampakines upregulate BDNF. Given the recent discoveries about the effects of BDNF - they are lasting effects - the Ampakines would potentially be effective even during long breaks between treatments.

A good analogy is to think of Asthma treatments. With cortisone, you have many negative effects with long-terms usage and virtually no side effects as long as you space the treatments enough. Cortisone is still effective between treatments because it prevents lung moulding.